Liposomes in Cancer Therapy: How Did We Start and Where Are We Now
Since their first discovery in the 1960s by Alec Bangham, liposomes have been shown to be effective drug delivery systems for treating various cancers. Several liposome-based formulations received approval by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), with many...
Main Authors: | Melody D. Fulton, Wided Najahi-Missaoui |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/7/6615 |
Similar Items
-
Recent Preclinical and Clinical Progress in Liposomal Doxorubicin
by: Kenan Aloss, et al.
Published: (2023-03-01) -
Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
by: Mohsen Ghaferi, et al.
Published: (2022-10-01) -
Safe Nanoparticles: Are We There Yet?
by: Wided Najahi-Missaoui, et al.
Published: (2020-12-01) -
Increased Targeting Area in Tumors by Dual-Ligand Modification of Liposomes with RGD and TAT Peptides
by: Mohamadreza Amin, et al.
Published: (2022-02-01) -
The Basement Membrane in a 3D Breast Acini Model Modulates Delivery and Anti-Proliferative Effects of Liposomal Anthracyclines
by: Tabea Wiedenhoeft, et al.
Published: (2020-09-01)